Stock Pick

Are these ASX shares too cheap to pass up?

Written by

openjargon

in

Group of successful real estate agents standing in building and looking at tablet.

Here at The Motley Fool, we are constantly sifting through the noise to find ASX shares that could be undervalued. 

Of course, not every down-and-out company is a value.

But here are three ASX shares that might have fallen too far to ignore. 

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation.

This ASX healthcare stock has fallen 22% year to date and more than 67% in the last 12 months. 

Yesterday, its share price closed at $8.84. 

However, it was just upgraded to a strong buy rating from analysts via the CommSec platform, which could indicate that it is now below fair value. 

This includes a buy rating from Citi with a $34 price target and a buy rating and $20 price target from TD Cowen. 

Bell Potter sits in the middle with a price target of $23.

From yesterday’s closing price, this indicates an upside between 126% and 284%. 

Block Inc (ASX: XYZ)

Block is a global company best known for providing payment-acquiring and related services to businesses.

Its share price is down almost 28% year to date and 46.8% over the last 12 months. 

Yesterday it closed at $70.47. 

Despite the fall, it did post some impressive profit results last year.

It has been dealing with headwinds like rising interest rates, sour buy now, pay later sentiment, and regulatory struggles. 

But with these ASX shares now close to 52-week lows, it could be simply too cheap to pass up. 

Recent analyst estimates include positive ratings and an average target price of $164.67. 

That indicates an upside of 133.6% for these battered ASX shares. 

Guzman y Gomez Ltd (ASX: GYG)

Guzman y Gomez is a Mexican-inspired quick-service restaurant operator and franchisor, mostly operating in Australia.

After a positive debut on the ASX back in mid-2024, it’s been a steady fall for these ASX shares. 

GYG shares are now down almost 55% in the last year, closing yesterday at $19.50. 

Despite the fall, sentiment for these ASX shares has started to turn, with experts seeing long-term value in the company. 

Earnings last year were positive; however, an important date to watch for prospective investors will be Friday, February 20, when the company releases H1 FY26 results.

Late last month, Morgans placed a buy rating and $32.30 price target on GYG shares thanks to optimism around new products. 

This indicates an upside of more than 65%. 

The post Are these ASX shares too cheap to pass up? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Telix Pharmaceuticals right now?

Before you buy Telix Pharmaceuticals shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 1 Jan 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Block and Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More posts